Medi-Caps loses CFO Hemant Sethi days after posting a ₹3 crore loss

Tipsheet Editorial — Mon, 08 Jun 2026 11:06:46 GMT

The nano-cap's chief financial officer resigned effective June 6 with no replacement named. The company just reported a full-year net loss of ₹3.04 crore.

What’s new

CFO Hemant Sethi resigned on June 6 to 'pursue career growth', effective immediately.
No successor has been named, leaving a key financial oversight role vacant.
The departure comes weeks after Medi-Caps reported a consolidated net loss of ₹3.04 crore for FY26.

Why it matters

A CFO exit at a nano-cap with a ₹37 crore market capitalisation and a widening loss is not routine turnover. It removes the person responsible for financial reporting at a company that can ill afford management instability. The absence of a named replacement adds operational uncertainty to an already difficult financial picture.

What we’re watching

Timeline for a CFO appointment — a prolonged vacancy is a red flag at this scale.
Whether the upcoming quarterly results carry any commentary on internal financial controls.
Any insider trades by Sethi in the period following his resignation.

The full read

Medi-Caps CFO Hemant Sethi quit on June 6. He was the finance chief at a ₹37 crore market-cap company that just posted a ₹3.04 crore net loss for FY26. The stated reason is career growth. No replacement has been named. For a company this small, the CFO is not just a senior hire; they are the primary person responsible for financial reporting and compliance. Losing that role without a transition plan introduces direct uncertainty into quarterly reporting and internal controls. The stock is already priced for trouble. A vacant CFO seat makes it harder to argue the ship is being steered.

Primary source: BSE · NSE

Medi-Caps swings to ₹303.75 lacs loss as revenue halves

Tipsheet Editorial — Thu, 21 May 2026 16:14:09 GMT

Consolidated revenue fell 51% to ₹1,244.85 lacs; standalone swung from profit to loss. Pharma division blames US political instability.

What’s new

Revenue from operations halved to ₹1,244.85 lacs from ₹2,547.71 lacs.
Consolidated net loss widened to ₹303.75 lacs from ₹57.10 lacs.
Standalone swung from ₹55.51 lacs profit to ₹13.87 lacs loss.

Why it matters

The scale of the revenue collapse — halved in a single year — points to deep structural issues in the pharma export business, especially the US market. At a ₹35 crore market cap, the company is now loss-making on both standalone and consolidated bases, leaving little margin for error.

What we’re watching

Whether US political conditions stabilise for the pharma division.
Any restructuring or cost-cutting measures announced.
Whether the standalone business can return to profitability.

The full read

Medi-Caps reported a sharp deterioration in FY26. Consolidated revenue halved to ₹1,244.85 lacs, and net loss ballooned to ₹303.75 lacs. The standalone entity, which had been profitable, also slipped into a loss of ₹13.87 lacs. The primary culprit: the pharma division, which generates the bulk of revenue, was hit by political instability in the US, its main export market. Meanwhile, the real estate segment, already weak, did not compensate. At a mere ₹35 crore market cap, the company is now loss-making on both bases. The next test is whether the US market recovers — and whether management can stem the bleeding in the pharma arm.

Primary source: BSE · NSE

Medi-Caps Ltd. (MEDICAPS) — Tipsheet

Medi-Caps loses CFO Hemant Sethi days after posting a ₹3 crore loss

What’s new

Why it matters

What we’re watching

The full read

Medi-Caps swings to ₹303.75 lacs loss as revenue halves

What’s new

Why it matters

What we’re watching

The full read